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Background
New antimalarials are needed to address the threat of
emerging artemisinin resistance. KAE609 is a spirotetra-
hydro-b-carbolines (spiroindolone) derivative and the
first molecule of this new class entering phase II studies.
Materials and methods
This first in human randomized, double-blind, placebo-
controlled, ascending single and multiple oral dose
study was designed to evaluate the safety, tolerability
and pharmacokinetics of KAE609 in healthy volunteers.
The study comprised of single ascending dose (1-300
mg, including one 30 mg food effect cohort, with 4-10
subjects in each cohort) and multiple ascending dose
(10-150 mg once daily for 3 days with 8 subjects in each
cohort) cohorts. The follow-up period was 6-8 days post
last dose. Safety and pharmacokinetics were assessed at
scheduled time points during the study.
Results
Of the total 95 male subjects enrolled, 93 completed the
study. Participants in both cohorts had comparable demo-
graphics. Systemic exposure in terms of AUCinf increased
in a dose-proportional manner over the dose range of 1-
300 mg. AUClast and Cmax also increased in an approxi-
mately dose-proportional manner in single and multiple
dose cohorts respectively, though not considered statisti-
cally dose-proportional. When administered daily for three
days, the accumulation ratio on Day 3 (AUC0-24, day 3/
AUC0-24, day 1) was in the range of 1.5-2.0 in the studied
dose range (10-150 mg) and consistent with an elimination
half-life of around 24 hours. Urine analysis for unchanged
KAE609 revealed negligible amounts (≤0.01%) excreted
renally. The high fat food intake with 30 mg single dose
did not affect the extent of KAE609 absorption however
Cmax was reduced by around 27% and increased Tmax
(from 2.5 to 4 hours). KAE609 was generally well tolerated
within this study, with transient gastrointestinal and geni-
tourinary adverse events of mild to moderate intensity,
which increased with rising doses.
Conclusions
KAE609 is a new antimalarial with potential to address
artemisinin resistance, and demonstrates a half-life of
around 24 hours and dose-proportional increase in sys-
temic exposure. KAE609 was generally well tolerated
within this study, with mild to moderate intensity gas-
trointestinal and genitourinary adverse events reported
with increasing dose. There were no study findings that
would preclude dosing in malaria patients and a human
malaria patient trial, which immediately followed this
study, showed that KAE609 clears parasitemia rapidly in
falciparum and vivax malaria patients.
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